JP6909924B2 - ベータ−ラクタマーゼ阻害剤およびその使用 - Google Patents
ベータ−ラクタマーゼ阻害剤およびその使用 Download PDFInfo
- Publication number
- JP6909924B2 JP6909924B2 JP2020512764A JP2020512764A JP6909924B2 JP 6909924 B2 JP6909924 B2 JP 6909924B2 JP 2020512764 A JP2020512764 A JP 2020512764A JP 2020512764 A JP2020512764 A JP 2020512764A JP 6909924 B2 JP6909924 B2 JP 6909924B2
- Authority
- JP
- Japan
- Prior art keywords
- oxy
- substituted
- oxo
- diazabicyclo
- octane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 **C(*)(*)COS(ON([C@@]1C*C(*)[C@@](C(N(*)*)=O)N2C1)C2=O)(=O)=O Chemical compound **C(*)(*)COS(ON([C@@]1C*C(*)[C@@](C(N(*)*)=O)N2C1)C2=O)(=O)=O 0.000 description 4
- BLJIEFRDZCJIAL-MSOLQXFVSA-N CC(C)(CC(C)(C)COS(ON([C@@H]1CC[C@@H](C(N)=O)N2C1)C2=O)(=O)=O)COC(c1ccccc1)=O Chemical compound CC(C)(CC(C)(C)COS(ON([C@@H]1CC[C@@H](C(N)=O)N2C1)C2=O)(=O)=O)COC(c1ccccc1)=O BLJIEFRDZCJIAL-MSOLQXFVSA-N 0.000 description 2
- HFMULVXNRIUPCV-UHFFFAOYSA-N CC(C)(C)C(OCCC(C)(C)COS(Cl)=O)=O Chemical compound CC(C)(C)C(OCCC(C)(C)COS(Cl)=O)=O HFMULVXNRIUPCV-UHFFFAOYSA-N 0.000 description 1
- DZBPKLAHGZTOKI-SJORKVTESA-N CC(C)(C)C(Oc1c(CC(C)(C)COS(ON([C@@H]2CC[C@@H](C(N)=O)N3C2)C3=O)(=O)=O)cccc1)=O Chemical compound CC(C)(C)C(Oc1c(CC(C)(C)COS(ON([C@@H]2CC[C@@H](C(N)=O)N3C2)C3=O)(=O)=O)cccc1)=O DZBPKLAHGZTOKI-SJORKVTESA-N 0.000 description 1
- HXDISZBXXZJPCP-UHFFFAOYSA-N CC(C)(C)OC(C(C)(C)COS(Cl)(=C)=O)=O Chemical compound CC(C)(C)OC(C(C)(C)COS(Cl)(=C)=O)=O HXDISZBXXZJPCP-UHFFFAOYSA-N 0.000 description 1
- MEQZWILNPLMCMK-SJORKVTESA-N CC(C)(C)OC(NCCONC([C@H](CC[C@H](C1)N2OCc3ccccc3)N1C2=O)=O)=O Chemical compound CC(C)(C)OC(NCCONC([C@H](CC[C@H](C1)N2OCc3ccccc3)N1C2=O)=O)=O MEQZWILNPLMCMK-SJORKVTESA-N 0.000 description 1
- JYVDPSDGMHSIHM-UHFFFAOYSA-N CC(C)(CC(C)(C)COC(c(c(OC)ccc1)c1OC)=O)CO Chemical compound CC(C)(CC(C)(C)COC(c(c(OC)ccc1)c1OC)=O)CO JYVDPSDGMHSIHM-UHFFFAOYSA-N 0.000 description 1
- XWFQWNXONZUSJA-UHFFFAOYSA-N CC(C)(CC(C)(C)COS(Cl)(=O)=O)COC(c1c(C)cccc1C)=O Chemical compound CC(C)(CC(C)(C)COS(Cl)(=O)=O)COC(c1c(C)cccc1C)=O XWFQWNXONZUSJA-UHFFFAOYSA-N 0.000 description 1
- MTJHDVVECRXWPJ-UHFFFAOYSA-N CC(C)(CC1(C)COCc2ccccc2)OC1=O Chemical compound CC(C)(CC1(C)COCc2ccccc2)OC1=O MTJHDVVECRXWPJ-UHFFFAOYSA-N 0.000 description 1
- XYFSHWJKAHGAJS-UHFFFAOYSA-N CC(C)(CC1(C)COS(Cl)(=O)=O)OC1=O Chemical compound CC(C)(CC1(C)COS(Cl)(=O)=O)OC1=O XYFSHWJKAHGAJS-UHFFFAOYSA-N 0.000 description 1
- QVRROEJLWBNOIH-UHFFFAOYSA-N CC(C)(CCCOC(c(c(OC)ccc1)c1OC)=O)CO Chemical compound CC(C)(CCCOC(c(c(OC)ccc1)c1OC)=O)CO QVRROEJLWBNOIH-UHFFFAOYSA-N 0.000 description 1
- FLQCZBVUDWRPOI-UHFFFAOYSA-N CC(C)(CCOC(c1ccccc1)=O)COS(Cl)(=O)=O Chemical compound CC(C)(CCOC(c1ccccc1)=O)COS(Cl)(=O)=O FLQCZBVUDWRPOI-UHFFFAOYSA-N 0.000 description 1
- FAOBCSSMMOHQBL-UHFFFAOYSA-N CC(C)(CO)C(C)(C)COC(c1ccccc1)=O Chemical compound CC(C)(CO)C(C)(C)COC(c1ccccc1)=O FAOBCSSMMOHQBL-UHFFFAOYSA-N 0.000 description 1
- WHYUTXFRDYGGEP-UHFFFAOYSA-N CC(C)(CO)COC(c1c(C)cccc1C)=O Chemical compound CC(C)(CO)COC(c1c(C)cccc1C)=O WHYUTXFRDYGGEP-UHFFFAOYSA-N 0.000 description 1
- DICBAKOMSMFQSQ-UHFFFAOYSA-N CC(C)(COS(Cl)=O)C(OCC(O1)=C(C)OC1=O)=O Chemical compound CC(C)(COS(Cl)=O)C(OCC(O1)=C(C)OC1=O)=O DICBAKOMSMFQSQ-UHFFFAOYSA-N 0.000 description 1
- AKQHRNFPFKIASS-MNOVXSKESA-N CC(C)(COS(ON([C@@H]1CC[C@@H](C(N)=O)N2C1)C2=O)(=O)=O)C(OCC(O1)=C(C)OC1=O)=O Chemical compound CC(C)(COS(ON([C@@H]1CC[C@@H](C(N)=O)N2C1)C2=O)(=O)=O)C(OCC(O1)=C(C)OC1=O)=O AKQHRNFPFKIASS-MNOVXSKESA-N 0.000 description 1
- HTGMNMOKKKLZSQ-CABCVRRESA-N CC(C)(COS(ON([C@@H]1CC[C@@H](C(N)=O)N2C1)C2=O)(=O)=O)C(OCc1ccccc1)=O Chemical compound CC(C)(COS(ON([C@@H]1CC[C@@H](C(N)=O)N2C1)C2=O)(=O)=O)C(OCc1ccccc1)=O HTGMNMOKKKLZSQ-CABCVRRESA-N 0.000 description 1
- SUADFFSZHUSHIU-UHFFFAOYSA-N CC(C)(Cc1ccccc1O1)C1=O Chemical compound CC(C)(Cc1ccccc1O1)C1=O SUADFFSZHUSHIU-UHFFFAOYSA-N 0.000 description 1
- MFEDJXSVJASESK-NEPJUHHUSA-N CCC(OCCC(C)(C)COS(ON([C@@H]1CC[C@@H](C(N)=O)N2C1)C2=O)(=O)=O)=O Chemical compound CCC(OCCC(C)(C)COS(ON([C@@H]1CC[C@@H](C(N)=O)N2C1)C2=O)(=O)=O)=O MFEDJXSVJASESK-NEPJUHHUSA-N 0.000 description 1
- UDTUWSBTBPKKSP-UHFFFAOYSA-N CCCCCCOC(C(C)(C)COS(Cl)(=O)=O)=O Chemical compound CCCCCCOC(C(C)(C)COS(Cl)(=O)=O)=O UDTUWSBTBPKKSP-UHFFFAOYSA-N 0.000 description 1
- VEZKHZZLNSAYMP-MNOVXSKESA-N CCOC(C(C)(COS(ON([C@@H]1CC[C@@H](C(N)=O)N2C1)C2=O)(=O)=O)C(OCC)=O)=O Chemical compound CCOC(C(C)(COS(ON([C@@H]1CC[C@@H](C(N)=O)N2C1)C2=O)(=O)=O)C(OCC)=O)=O VEZKHZZLNSAYMP-MNOVXSKESA-N 0.000 description 1
- FMICXZDPZHTINW-RTWAWAEBSA-N CCOC(C1(COS(ON([C@@H]2CC[C@@H](C(NC(CC3)CCN3C(OC(C)(C)C)=O)=O)N3C2)C3=O)(=O)=O)CCCCC1)=O Chemical compound CCOC(C1(COS(ON([C@@H]2CC[C@@H](C(NC(CC3)CCN3C(OC(C)(C)C)=O)=O)N3C2)C3=O)(=O)=O)CCCCC1)=O FMICXZDPZHTINW-RTWAWAEBSA-N 0.000 description 1
- VOCAIDDBEJJKHT-UHFFFAOYSA-N CCOC(CCC(C)(C)COS(Cl)(=O)=O)=O Chemical compound CCOC(CCC(C)(C)COS(Cl)(=O)=O)=O VOCAIDDBEJJKHT-UHFFFAOYSA-N 0.000 description 1
- MBGNLKNZEUPWFE-NEPJUHHUSA-N CCOC(CCC(C)(C)COS(ON([C@@H]1CC[C@@H](C(N)=O)N2C1)C2=O)(=O)=O)=O Chemical compound CCOC(CCC(C)(C)COS(ON([C@@H]1CC[C@@H](C(N)=O)N2C1)C2=O)(=O)=O)=O MBGNLKNZEUPWFE-NEPJUHHUSA-N 0.000 description 1
- QSZUBQFEBLTEHN-QROGQSHRSA-N CC[U]C(C(C)(C)COS([U]N([C@@H]1CC[C@@H](C(N)=C)N2C1)C2=[U])(=O)=[U])=[U] Chemical compound CC[U]C(C(C)(C)COS([U]N([C@@H]1CC[C@@H](C(N)=C)N2C1)C2=[U])(=O)=[U])=[U] QSZUBQFEBLTEHN-QROGQSHRSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cephalosporin Compounds (AREA)
- Medicinal Preparation (AREA)
- Storage Device Security (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021111184A JP2021165298A (ja) | 2017-05-10 | 2021-07-05 | ベータ−ラクタマーゼ阻害剤およびその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762504523P | 2017-05-10 | 2017-05-10 | |
| US62/504,523 | 2017-05-10 | ||
| US201762551043P | 2017-08-28 | 2017-08-28 | |
| US62/551,043 | 2017-08-28 | ||
| US15/934,497 US10085999B1 (en) | 2017-05-10 | 2018-03-23 | Beta-lactamase inhibitors and uses thereof |
| US15/934,497 | 2018-03-23 | ||
| PCT/US2018/030652 WO2018208557A1 (en) | 2017-05-10 | 2018-05-02 | 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021111184A Division JP2021165298A (ja) | 2017-05-10 | 2021-07-05 | ベータ−ラクタマーゼ阻害剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020519684A JP2020519684A (ja) | 2020-07-02 |
| JP2020519684A5 JP2020519684A5 (enExample) | 2021-02-04 |
| JP6909924B2 true JP6909924B2 (ja) | 2021-07-28 |
Family
ID=63639355
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020512764A Active JP6909924B2 (ja) | 2017-05-10 | 2018-05-02 | ベータ−ラクタマーゼ阻害剤およびその使用 |
| JP2021111184A Pending JP2021165298A (ja) | 2017-05-10 | 2021-07-05 | ベータ−ラクタマーゼ阻害剤およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021111184A Pending JP2021165298A (ja) | 2017-05-10 | 2021-07-05 | ベータ−ラクタマーゼ阻害剤およびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US10085999B1 (enExample) |
| EP (1) | EP3625233B9 (enExample) |
| JP (2) | JP6909924B2 (enExample) |
| KR (1) | KR102411517B1 (enExample) |
| CN (1) | CN110662746B (enExample) |
| AU (2) | AU2018266566B2 (enExample) |
| CA (2) | CA3153583A1 (enExample) |
| DK (1) | DK3625233T5 (enExample) |
| ES (1) | ES2955871T3 (enExample) |
| FI (1) | FI3625233T5 (enExample) |
| HR (1) | HRP20230977T1 (enExample) |
| HU (1) | HUE062752T2 (enExample) |
| IL (2) | IL296379B2 (enExample) |
| LT (1) | LT3625233T (enExample) |
| MX (2) | MX385265B (enExample) |
| PL (1) | PL3625233T3 (enExample) |
| PT (1) | PT3625233T (enExample) |
| RS (1) | RS64547B9 (enExample) |
| RU (1) | RU2753401C2 (enExample) |
| SG (2) | SG10202102306TA (enExample) |
| SI (1) | SI3625233T1 (enExample) |
| WO (1) | WO2018208557A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017290060B2 (en) | 2016-06-30 | 2021-07-22 | Qpex Biopharma, Inc | Boronic acid derivatives and therapeutic uses thereof |
| US10085999B1 (en) * | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
| MX2020004071A (es) * | 2017-10-02 | 2020-07-28 | Arixa Pharmaceuticals Inc | Derivados de aztreonam y usos de los mismos. |
| CN112424209A (zh) | 2018-04-20 | 2021-02-26 | Qpex生物制药有限公司 | 硼酸衍生物及其治疗用途 |
| ES2991492T3 (es) | 2018-10-01 | 2024-12-03 | Arixa Pharmaceuticals Inc | Derivados de relebactam y usos de los mismos |
| US11008321B2 (en) * | 2019-03-12 | 2021-05-18 | Arixa Pharmaceuticals, Inc. | Crystalline form of an avibactam derivative |
| EP3959205B1 (en) | 2019-04-26 | 2025-11-12 | Merck Sharp & Dohme LLC | Process for the preparation of intermediates useful for making (2s,5r)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide |
| US12636297B2 (en) | 2019-06-19 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| EP4021443A1 (en) * | 2019-08-29 | 2022-07-06 | Arixa Pharmaceuticals, Inc. | Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections |
| US20210186983A1 (en) * | 2019-12-20 | 2021-06-24 | Arixa Pharmaceuticals, Inc. | Orally administered combinations of amoxicillin and avibactam derivatives for treating mycobacterial infections |
| US12637481B2 (en) | 2020-03-18 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| IL297458A (en) | 2020-05-05 | 2022-12-01 | Qpex Biopharma Inc | Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses |
| CN111943950B (zh) * | 2020-09-10 | 2022-03-29 | 山东安信制药有限公司 | 一种瑞来巴坦的制备方法 |
| EP4319760A4 (en) * | 2021-04-05 | 2025-01-08 | Qpex Biopharma, Inc. | CEFTIBUTENE DOSAGE REGIMEN |
| CN113559099A (zh) * | 2021-08-27 | 2021-10-29 | 丹诺医药(苏州）有限公司 | 包含舒巴坦和阿维巴坦的药物组合物及其应用 |
| CN115448920B (zh) * | 2022-10-14 | 2025-01-03 | 广州楷石医药有限公司 | 一种β-内酰胺酶抑制剂及其应用 |
| GB202306833D0 (en) | 2023-05-09 | 2023-06-21 | Adjutec Pharma As | Therapy |
| GB202306826D0 (en) | 2023-05-09 | 2023-06-21 | Adjutec Pharma As | Therapy |
| CN119431373B (zh) * | 2024-07-24 | 2025-08-08 | 科睿迪(南京)医药科技有限公司 | 一种β-内酰胺酶抑制剂及其用途 |
| WO2026043829A1 (en) * | 2024-08-21 | 2026-02-26 | Merck Sharp & Dohme Llc | Chromane cyclic amidine monobactam compounds for the treatment of bacterial infections |
| WO2026058228A1 (en) | 2024-09-16 | 2026-03-19 | Pfizer Inc. | Process to prepare avibactam tomilopil |
| CN122079989A (zh) * | 2024-09-30 | 2026-05-26 | 科睿迪(南京)医药科技有限公司 | 二氮杂二环类β-内酰胺酶抑制剂及其应用 |
| WO2026104587A1 (en) | 2024-11-13 | 2026-05-21 | Adjutec Pharma As | Cyclic boronic acid esters useful as adjuvants in the treatment of bacterial infections |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3658849A (en) | 1969-02-19 | 1972-04-25 | Reynolds Tobacco Co R | Treatment of 2-substituted aldehydes with lead dioxide |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| USRE28819E (en) | 1972-12-08 | 1976-05-18 | Syntex (U.S.A.) Inc. | Dialkylated glycol compositions and medicament preparations containing same |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| DE3045373A1 (de) | 1980-12-02 | 1982-07-01 | Henkel KGaA, 4000 Düsseldorf | Verwendung von estern der 3-hydrody-2,2-dimethylpropionsaeure als riechstoffe, diese enthaltende riechstoffkompositionen und 3-hydroxy-2,2-dimethyl-propionsaeurepropylester |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4358603A (en) | 1981-04-16 | 1982-11-09 | Syntex (U.S.A.) Inc. | Acetal stabilized prostaglandin compositions |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| KR890002631B1 (ko) | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| US6024975A (en) | 1992-04-08 | 2000-02-15 | Americare International Diagnostics, Inc. | Method of transdermally administering high molecular weight drugs with a polymer skin enhancer |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US5983134A (en) | 1995-04-23 | 1999-11-09 | Electromagnetic Bracing Systems Inc. | Electrophoretic cuff apparatus drug delivery system |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| DE69632684T2 (de) | 1995-06-27 | 2005-06-09 | Takeda Pharmaceutical Co. Ltd. | Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung |
| US6167301A (en) | 1995-08-29 | 2000-12-26 | Flower; Ronald J. | Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| US5985317A (en) | 1996-09-06 | 1999-11-16 | Theratech, Inc. | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents |
| WO1998014179A1 (en) | 1996-10-01 | 1998-04-09 | Cima Labs Inc. | Taste-masked microcapsule compositions and methods of manufacture |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| ES2221019T3 (es) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| EP0946169B1 (en) | 1996-12-20 | 2003-02-26 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US5860957A (en) | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| NZ505651A (en) | 1998-01-16 | 2003-08-29 | Takeda Chemical Industries Ltd | Sustained release composition comprising biologically active substance, hydroxynaphthoic acid and biodegradable polymer |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
| US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
| FR2812635B1 (fr) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
| WO2002092606A1 (en) | 2001-05-15 | 2002-11-21 | Takeda Chemical Industries, Ltd. | Fused imidazolidine derivatives, process for preparation of the same and use thereof |
| EP1663159A4 (en) | 2003-09-10 | 2010-06-09 | Map Pharmaceuticals Inc | AEROSOL FORMULATIONS FOR THE DELIVERY OF DIHYDROERGOTAMINE TO THE SYSTEMIC CIRCULATION BY PULMONARY INHALATION |
| UY30244A1 (es) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | Un proceso para preparar derivados de tetrahidroquinolina |
| WO2009033079A1 (en) | 2007-09-07 | 2009-03-12 | Xenoport, Inc. | Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| TW200924746A (en) | 2007-09-07 | 2009-06-16 | Xenoport Inc | Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| US20090099253A1 (en) | 2007-10-15 | 2009-04-16 | Xenoport, Inc. | Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use |
| JP5038509B2 (ja) * | 2008-01-18 | 2012-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | β−ラクタマーゼ阻害剤 |
| GB0801401D0 (en) | 2008-01-25 | 2008-03-05 | Barry Callebaut Ag | Composition |
| US8987468B2 (en) | 2008-02-04 | 2015-03-24 | The Translational Genomics Research Institute | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives |
| US8722686B2 (en) | 2008-09-19 | 2014-05-13 | Pfizer Inc. | Hydroxamic acid derivatives useful as antibacterial agents |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| WO2010126820A2 (en) | 2009-04-30 | 2010-11-04 | Merck Sharp & Dohme Corp. | Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids |
| CA2777043C (en) | 2009-10-14 | 2015-12-15 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
| RS59255B1 (sr) | 2010-04-20 | 2019-10-31 | Fujifilm Toyama Chemical Co Ltd | Derivat hidroksaminske kiseline |
| WO2011150380A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
| DE102010033015B4 (de) | 2010-07-31 | 2016-03-17 | Gaplast Gmbh | Einmal-Applikator |
| US8772490B2 (en) | 2010-12-22 | 2014-07-08 | Meiji Seika Pharma Co., Ltd. | Optically active diazabicyclooctane derivatives and process for preparing the same |
| SI2657234T1 (sl) | 2010-12-22 | 2017-06-30 | Meiji Seika Pharma Co., Ltd. | Derivat optično-aktivnega diazabiciklooktana in metoda za njegovo izdelavo |
| AR086590A1 (es) | 2011-05-30 | 2014-01-08 | Sumitomo Chemical Co | Compuestos de ciclohexanona y herbicidas que los comprenden |
| US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
| AR090539A1 (es) * | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | COMPUESTOS INHIBIDORES DE b LACTAMASA |
| HUE046893T2 (hu) * | 2012-05-30 | 2020-04-28 | Meiji Seika Pharma Co Ltd | Új ß-laktamáz inhibitor és eljárás elõállítására |
| EP3131583A1 (en) | 2014-04-18 | 2017-02-22 | The Wockhardt Limited | Pharmaceutical compositions comprising antibacterial agents |
| CN106794162A (zh) | 2014-09-12 | 2017-05-31 | 富山化学工业株式会社 | 组合使用新的异羟肟酸衍生物和抗菌性物质的方法 |
| CA2960949A1 (en) | 2014-09-12 | 2016-03-17 | Tatsuya Honda | Novel pharmaceutical composition containing hydroxamic acid derivative or salt thereof |
| WO2016116788A1 (en) | 2015-01-24 | 2016-07-28 | Wockhardt Limited | Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections |
| WO2017037607A1 (en) * | 2015-09-01 | 2017-03-09 | Wockhardt Limited | (aminomethylidene)amino-substituted (2s,5r)-6-(sulfonyl)-7-oxo-1,6-diazabicyclo[3.2.1 ]octane-2-carboxamide derivatives with antibacterial activity |
| CA2984024A1 (en) | 2015-09-16 | 2017-03-23 | Xuanzhu Pharma Co., Ltd. | .beta.-lactamase inhibitors and uses thereof |
| US20170165371A1 (en) | 2017-02-22 | 2017-06-15 | Joel Steven Goldberg | Novel synthesis of potential ester prodrugs |
| US10085999B1 (en) * | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
-
2018
- 2018-03-23 US US15/934,497 patent/US10085999B1/en active Active
- 2018-05-02 ES ES18729223T patent/ES2955871T3/es active Active
- 2018-05-02 AU AU2018266566A patent/AU2018266566B2/en active Active
- 2018-05-02 EP EP18729223.0A patent/EP3625233B9/en active Active
- 2018-05-02 KR KR1020197036316A patent/KR102411517B1/ko active Active
- 2018-05-02 HU HUE18729223A patent/HUE062752T2/hu unknown
- 2018-05-02 SG SG10202102306TA patent/SG10202102306TA/en unknown
- 2018-05-02 DK DK18729223.0T patent/DK3625233T5/da active
- 2018-05-02 CN CN201880030530.7A patent/CN110662746B/zh active Active
- 2018-05-02 CA CA3153583A patent/CA3153583A1/en active Pending
- 2018-05-02 PT PT187292230T patent/PT3625233T/pt unknown
- 2018-05-02 IL IL296379A patent/IL296379B2/en unknown
- 2018-05-02 RU RU2019135891A patent/RU2753401C2/ru active
- 2018-05-02 HR HRP20230977TT patent/HRP20230977T1/hr unknown
- 2018-05-02 FI FIEP18729223.0T patent/FI3625233T5/fi active
- 2018-05-02 SG SG11201909429V patent/SG11201909429VA/en unknown
- 2018-05-02 RS RS20230696A patent/RS64547B9/sr unknown
- 2018-05-02 MX MX2019013260A patent/MX385265B/es unknown
- 2018-05-02 CA CA3062619A patent/CA3062619C/en active Active
- 2018-05-02 JP JP2020512764A patent/JP6909924B2/ja active Active
- 2018-05-02 WO PCT/US2018/030652 patent/WO2018208557A1/en not_active Ceased
- 2018-05-02 LT LTEPPCT/US2018/030652T patent/LT3625233T/lt unknown
- 2018-05-02 SI SI201830972T patent/SI3625233T1/sl unknown
- 2018-05-02 PL PL18729223.0T patent/PL3625233T3/pl unknown
- 2018-08-29 US US16/116,489 patent/US10500211B2/en active Active
-
2019
- 2019-10-16 US US16/654,281 patent/US10722521B2/en active Active
- 2019-10-31 IL IL270330A patent/IL270330B2/en unknown
- 2019-11-06 MX MX2021008379A patent/MX2021008379A/es unknown
-
2020
- 2020-06-08 US US16/895,033 patent/US20200297733A1/en not_active Abandoned
- 2020-09-03 AU AU2020227077A patent/AU2020227077B2/en active Active
-
2021
- 2021-07-05 JP JP2021111184A patent/JP2021165298A/ja active Pending
-
2023
- 2023-02-28 US US18/176,048 patent/US20230201218A1/en not_active Abandoned
-
2024
- 2024-08-14 US US18/805,384 patent/US20240415847A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021165298A (ja) | ベータ−ラクタマーゼ阻害剤およびその使用 | |
| JP6991345B2 (ja) | アズトレオナム誘導体およびその使用 | |
| AU2020237440B2 (en) | Crystalline form of an avibactam derivative | |
| JP7437847B2 (ja) | レレバクタムの誘導体およびその使用 | |
| RU2815314C2 (ru) | Ингибиторы бета-лактамаз и их применение | |
| HK40016559A (en) | Compounds as perorally administered prodrugs of beta-lactamase inhibitors, pharmaceutical compositions thereof and use for treating bacterial infections | |
| HK40016559B (en) | Compounds as perorally administered prodrugs of beta-lactamase inhibitors, pharmaceutical compositions thereof and use for treating bacterial infections | |
| BR112019023598B1 (pt) | COMPOSTOS INIBIDORES DE ß-LACTAMASE, COMPOSIÇÕES FARMACÊUTICAS E SEUS USOS | |
| NZ758795B2 (en) | Atropine pharmaceutical compositions | |
| NZ758795A (en) | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200319 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20201126 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20201126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201204 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201204 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20201204 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20201218 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20201225 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210209 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210406 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210608 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210705 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6909924 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |